Comprehensive Molecular Profiling Linked to Improved Survival in NSCLC

Key Clinical Summary

• Comprehensive molecular profiling (CMP) was associated with longer overall survival (OS) and lower health care utilization among patients with non–small cell lung cancer (NSCLC).
• According to data pulled from TriNetX, the median OS was 1784 days with CMP vs 1074 days without; Highmark Health data similarly showed higher 4-year OS with molecular testing (55% vs 43%).
• Highmark Health data showed that survival gains associated with molecular testing occurred without a statistically significant increase in total cost per patient per month during follow-up (P = .083).

CMP was associated with improved survival and reduced health care utilization among patients with NSCLC, according to an analysis of 2 independent real-world datasets. Despite longstanding guideline recommendations for CMP in advanced NSCLC, investigators found that fewer than 1 in 15 patients in the TriNetX cohort underwent molecular profiling.

Real-World Molecular Profiling and Survival Outcomes

Researchers evaluated the real-world impact of molecular profiling on survival, health care utilization, and costs among adults with NSCLC treated between January 2019 and December 2025. Data were obtained from TriNetX and Highmark Health, and patients were categorized according to whether they received broad-panel molecular profiling consistent with guideline-directed indications.

Among 33 977 patients with NSCLC in the TriNetX dataset, 2354 (6.9%) underwent molecular profiling. Patients who received profiling had a median OS of 1784 days compared with 1074 days among patients who were not tested. After adjustment for clinical factors, molecular profiling was associated with a lower risk of death (adjusted hazard ratio, 0.61; P < .001).

Health care utilization was also lower among molecularly profiled patients. These patients had fewer inpatient admissions than untested patients (0.651 vs 0.875; P < .001) and fewer emergency department visits (0.437 vs 0.583; P = .047).

Findings from the Highmark Health dataset independently showed higher 4-year OS among molecularly tested patients, at 55% compared with 43% among untested patients (P < .001). The survival difference was observed without a statistically significant increase in total cost per patient per month during follow-up (P = .083).

Value of Molecular Profiling in NSCLC Care

CMP can identify actionable driver alterations in advanced NSCLC and help guide patients toward matched targeted therapies. The findings suggest that molecular profiling may provide clinical and health care utilization benefits without significantly increasing overall costs.

However, the low rate of molecular profiling observed in the TriNetX cohort highlights a gap between guideline recommendations and real-world testing. According to the researchers, standardized and reflexive molecular testing at diagnosis may help increase implementation of precision oncology for patients with advanced NSCLC.

The findings also provide real-world evidence supporting the potential value of molecular profiling beyond treatment selection. Lower inpatient and emergency department utilization, combined with improved survival without significantly higher overall costs, may be particularly relevant to health systems and payers evaluating precision oncology strategies.

Addressing Gaps in Molecular Testing

The researchers characterized the observed underuse of molecular profiling as a persistent failure to implement guideline-concordant care. They concluded that the findings support “the value-based impact of precision oncology” and called for “standardized and reflexive molecular testing at diagnosis” to help ensure precision medicine is delivered as standard care for patients with advanced NSCLC.

Across 2 independent real-world datasets, molecular profiling was associated with improved survival and lower health care utilization in NSCLC without significantly higher overall costs. The findings highlight continued opportunities to increase guideline-concordant molecular testing and expand access to precision oncology.

Reference

Ozogbo SI, Gadela T, Chattaraj A, et al. Comprehensive molecular profiling in advanced non–small cell lung cancer (NSCLC): measurable survival and value impacts of implementation. J Clin Oncol. 2026;44(16_suppl):11054. doi:10.1200/JCO.2026.44.16_suppl.11054